Compare WVE & CRVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | CRVL |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2015 | 1995 |
| Metric | WVE | CRVL |
|---|---|---|
| Price | $13.35 | $51.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $31.47 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 216.9K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.53 |
| Revenue | $3,704,000.00 | ★ $895,589,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.93 | N/A |
| P/E Ratio | ★ N/A | $33.86 |
| Revenue Growth | ★ 149.43 | 12.61 |
| 52 Week Low | $5.28 | $44.83 |
| 52 Week High | $21.73 | $117.70 |
| Indicator | WVE | CRVL |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 41.50 |
| Support Level | $12.53 | $47.00 |
| Resistance Level | $14.56 | $55.33 |
| Average True Range (ATR) | 0.79 | 1.92 |
| MACD | 0.01 | 0.70 |
| Stochastic Oscillator | 23.84 | 54.32 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.